Recombinant Human TIM-4 Fc Chimera Protein, CF

Recombinant Human TIM-4 Fc Chimera (Catalog #9300-TM)inhibits anti-CD3-induced proliferation of human T cells. The ED50 for thiseffect is 0.15-0.75 μg/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human TIM-4 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated human T cells. The ED₅₀ for this effect is 0.15-0.75 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human TIM-4 protein
  

  Human TIM-4 (Glu25-Gln314) Accession # Q96H15	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q96H15
• N-terminal Sequence: Glu25
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 58 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 95-113 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human TIM-4 Fc Chimera Protein, CF

• FLJ27515
• Smuckler
• T-cell immunoglobulin and mucin domain containing 4
• T-cell immunoglobulin and mucin domain-containing protein 4
• T-cell membrane protein 4
• TIM4
• TIM-4
• TIMD4
• TIMD-4

Background

TIM-4 (T cell; immunoglobulin; mucin-4), also known as SMUCKLER,  is a 60 kDa member of the TIM family of immune regulating proteins. TIMs are type I transmembrane proteins with one Ig-like V domain and one Ser/Thr-rich mucin domain (1). Mature human TIM-4 consists of a 290 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 43 aa cytoplasmic tail (2). Structurally, TIM-4 is distinguished from other TIMs by the presence of an RGD motif in its Ig domain and the lack of a site for tyrosine phosphorylation in its cytoplasmic tail. Within the ECD human TIM-4 shares 45% aa sequence identity with mouse and rat TIM-4. TIM-4 is expressed by macrophages and mature dendritic cells but not by lymphocytes (2, 3). It binds specifically to TIM-1 which is also the cellular receptor for hepatitis A virus and has been implicated in the development of asthma (3-5). Among hematopoietic cells, TIM-1 is expressed on activated B and T cells, preferentially in the Th2 subset of CD4⁺ T cells (3, 6). The interaction of TIM-4 with TIM-1 induces co-stimulatory and hyperproliferative signals in T cells (3). TIM-4 also binds to phosphatidylserine (PS) on the surface of apoptotic cells (7). It enhances the clearance of apoptotic cells including T cells in the contraction phase of immune responses, apoptotic macrophages that accumulate in atherosclerosis, and dying neurons in the brain (7-10). TIM-4 is upregulated on some tumor cells and tumor-associated myeloid cells where it binds Integrin alpha V beta 3, contributes to tumor progression, and inhibits tumor-specific cellular immunity (11, 12).

1. Fang, X.Y. et al. (2015) Autoimmunity 48:189.
2. Shakhov, A.N. et al. (2004) Eur. J. Immunol. 34:494.
3. Meyers, J.H. et al. (2005) Nat. Immunol. 6:455.
4. Feigelstock, D. et al. (1998) J. Virol. 72:6621.
5. McIntire, J.J. et al. (2001) Nat. Immunol. 2:1109.
6. Khademi, M. et al. (2004) J. Immunol. 172:7169.
7. Kobayashi, N. et al. (2007) Immunity 27:927.
8. Albacker, L.A. et al. (2010) J. Immunol. 185:6839.
9. Mazaheri, F. et al. (2014) Nat. Commun. 5:4046.
10. Foks, A.C. et al. (2016) Arterioscler. Thromb. Vasc. Biol. 36:456.
11. Zhang, Q. et al. (2015) Br. J. Cancer 113:1484.
12. Baghdadi, M. et al. (2013) Immunity 39:1070.

Bioinformatics

• Uniprot:
  • Q96H15()